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Abstract
Pharmacogenetics as a tool to aid clinicians implement individualized pharmacotherapy is utilized
in some areas of medicine. Pharmacogenetics in pregnancy is still a developing field. However,
there are several areas of obstetric therapeutics where data are emerging that give glimpses into
future therapeutic possibilities. These include opioid pain management, antihypertensive therapy,
antidepressant medications, preterm labor tocolytics, antenatal corticosteroids and drugs for
nausea and vomiting of pregnancy, to name a few. More data are needed to populate the
therapeutic models and to truly determine if pharmacogenetics will aid in individualizing
pharmacotherapy in pregnancy. The objective of this review is to summarize current data and
highlight research needs.
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The right drug, at the right dose, given at the right time, for the right patient. This is an ideal
that all healthcare practitioners strive toward when prescribing drugs to patients. This is
particularly important for medications and conditions that have a high risk of adverse events
or for drugs with narrow therapeutic windows. Additionally, pregnancy is a condition that is
particularly enticing for the above mantra. Because of the presence of the developing fetus
and the maternal changes that are occurring, pregnancy therapeutics offers particular
challenges for the clinician. The goals of individualizing pharmacotherapy in pregnancy
require information and tools to truly optimize care.
Pregnant women often need therapeutic drugs. Over 95% of women take a prescription drug
or supplement during their pregnancy [1,2]. This includes over 65% of women taking a
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prescription drug other than prenatal vitamins and iron [1,2]. Not only do women with
medical conditions become pregnant and require continued drug therapy, but pregnant
women also develop conditions that require drug therapy. As pregnancy-specific dosing of
drugs is almost universally lacking, providers are reliant upon dosing regimens in package
inserts, usually derived from studies in healthy males [3]. In fact, the US National Research
Act of 1974 codified the exclusion of reproductive-aged women from many trials to avoid
accidental early fetal exposure to drugs. However, in 1993 the NIH in the US shifted the
paradigm and required the inclusion of women in trials unless there was a reason not to. This
included guidance on the inclusion of pregnant women.
Because pregnant women were excluded from clinical drug trials for so long there are only
scant data regarding drug concentrations in pregnant women for many therapeutics. This
trend does seem to be changing however. In the last 2 years, there were noted to be 264
registered clinical trials of drugs used in pregnancy [4]. Of these registered trials, 28 (10.6%)
specifically were noted to be reporting pharmacokinetic data in pregnant women [4]. This is
important as reports recently have noted that drug concentrations in pregnant women are
much lower than nonpregnant controls for many medications including antibiotic,
antihypertensive and antiretroviral drugs to name a few [5–9]. Much of this change is due to
the myriad physiological changes in pregnancy that are catalogued elsewhere [10]. The work
of several international groups, including the US NIH-funded Obstetric-Fetal Pharmacology
Research Units Network [101], is aimed at closing this gap in pharmacokinetic and
pharmacodynamic data in pregnancy. The purpose of this review is to describe
pharmacogenetics used in current therapeutics, to describe current obstetric
pharmacogenetic findings and research, and to describe what is needed to ensure the future
of pharmacogenetics and individualized pharmacotherapy in pregnancy.
Pharmacogenetics currently utilized in therapeutics
Pharmacogenetics refers to the study of individual candidate genes as a powerful tool to help
explain interindividual variability in drug response [11]. This pertains to both therapeutic as
well as adverse effects. It is well recognized that metabolized drugs exhibit the most
pharmacokinetic variability. The majority of this variability is due to inconsistencies in the
ability of enzymes in the liver and gastrointestinal tract to carry out drug metabolism. The
key enzymes involved in metabolic variation include the CYP450 family of drug-
metabolizing enzymes, which carry out phase 1 drug metabolism, but also the phase 2
enzymes, including the enzymes that carry out acetylation, glucuronidation, sulfation,
methylation and the addition of glutathione. Many of these enzymes have SNPs that can lead
to increased or decreased activity, accounting for some of the observed variation in drug
concentrations and response. Additionally, there are SNPs responsible for receptor
modifications that may impact the binding of a drug to its target. This could lead to no
effect, decreased effect or too great of an effect. Pharmacogenetics studies seek to describe
effect variation and relate it to genetic SNP differences in an effort to better predict response
and minimize adverse effects.
Pharmacogenetics has had slow uptake into clinical practice however. Factors leading to this
include: high cost of the tests, lack of knowledge about the tests and how to apply them by
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clinicians, the need for specialized laboratory equipment to perform the tests, difficulty with
interpretation of tests, and the lack of proven utility of several of the pharmacogenetic tests
[12].
Despite these limitations, there are several pharmacogenetic tests currently used in clinical
practice. As of July 2011, there were 15 different drugs or drug classes with commercially
available pharmacogenetic tests. Several of these tests are now standard of care in
therapeutics. A mutation in the KRAS gene codon 12 or 13 leads to resistance to cetuximab
therapy. Thus, the American Society of Clinical Oncology has recommended that all
patients with metastatic colorectal carcinoma who are candidates for cetuximab therapy
should have their tumor tested for KRAS mutations. If codon 12 or 13 mutations are
detected, then the patients should not receive the expensive cetuximab therapy as part of
their treatment [13]. The cutaneous adverse drug reaction Stevens–Johnson syndrome is a
serious concern for people taking drugs such as abacavir and carbamazepine [14,15].
Pharmacogenetic screening for HLA-B*5701 can help identify those taking abacavir most at
risk for developing this severe adverse drug reaction. To avoid Stevens–Johnson syndrome,
this test is now widely used for screening patients in need of abacavir in the developed
world [16]. The BCR-ABL gene negates the benefits of imatinib therapy for those with
chronic myelogenous leukemia and thus the therapy is not recommended for those carrying
that gene. Other pharmacogenetic tests that similarly have data supporting their potential
role for individualizing drug therapy are the CYP2D6 test for tamoxifen [17,18] or
venlafaxine [19], the CYP2C19 test for clopidogrel antiplatelet therapy [20], and the
CYP2C9 and VKCOR test for those starting warfarin therapy [21–23].
These tests and pharmacogenetic findings are becoming much more common. In fact, one
study revealed that nearly one-quarter of all outpatients received at least one drug with
pharmacogenomic information in the label for that drug [24]. Table 1 displays a list of drug-
metabolizing enzymes and receptors that have polymorphic expression and some of the
drugs that are relevant to that drug. While pregnancy therapeutics is behind other therapeutic
areas in researching pharmacogenetics, data are emerging in several areas that may pave the
way toward a greater importance of pharmacogenetics in pregnancy.
Codeine & opioid pain
Opioid analgesics frequently are used for peripartum pain relief. As codeine and other
narcotic pain medications are prodrugs requiring conversion to morphine and other active
metabolites for their action, metabolizing enzymes are important to consider. For instance
codeine requires metabolism by CYP2D6 into the active metabolite morphine. CYP2D6 is
an enzyme that is highly polymorphic and is actually induced through the course of
pregnancy [25,26]. Women who possess certain SNPs in CYP2D6 are categorized as poor
metabolizers (Table 1). These women do not receive adequate pain relief from codeine as it
is not well transformed into active morphine. Conversely, some individuals possess many
copies of the CYP2D6 gene and are either extensive metabolizers (EMs) or ultra-rapid
metabolizers (UMs). These women would convert codeine to morphine in a normal way or
in an excessive way, respectively. People who are UMs might get rapid pain relief but also
be more prone to side effects [27–29]. The presence of these SNPs can be particularly
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relevant depending on the woman’s SNPs in UGT. UGT facilitates the excretion of opioids
from the body [27]. The combination of CYP2D6 UM status of the mother and infants with
a UGTB7*2 genotype, indicative of reduced activity, can lead to toxicity of morphine in
breastfeeding infants [30]. Because these findings have explained infant deaths, the US FDA
issued a Public Health Advisory for women who are breastfeeding and taking narcotics
[102]. In addition, the EMA’s Pharmacovigilance Risk Assessment Committee also
discourages codeine use by breastfeeding women or for any patient who is known to be a
CYP2D6 UM [103].
Thus, for women planning to breastfeed who will require narcotic pain medication in the
postpartum period, codeine may not be the best choice for analgesia [31]. While other opioid
pain medications also are metabolized by CYP2D6, many of them also are metabolized
through other CYP450 pathways, thus potentially ameliorating some of the impact of
CYP2D6 metabolism status on pain control and side effects. The importance of these SNPs
with other opioids in the peripartum period is being investigated. However, it is being noted
that pharmacogenetics is an important factor in life-threatening adverse events among opioid
users [32]. This is an active area of research. While guidelines have not been issued as a
result of this research yet, obstetric practitioners should be aware of developments in this
area.
Antihypertensive medications
Hypertension complicates 12–22% of pregnancies [33]. Whether being treated for chronic
hypertension or for acutely elevated blood pressures with preeclampsia, many pregnant
women require antihypertensive drugs. β-blockers are commonly used antihypertensive
drugs. Drugs in this category such as metoprolol and propranolol are metabolized by
CYP2D6. As demonstrated already, CYP2D6 activity increases throughout pregnancy.
Thus, later in pregnancy, someone who had previously been controlled on her medication
may begin to show signs of worsening hypertension [34]. Up to 7% of the US major ethnic
populations are UMs, with gene duplication UMs as high as 45% in Asians [35,36]. As
pregnancy progresses, EMs and UMs have more enzymatic activity, whereas poor
metabolizers have suppressed activity [26,37]. Thus, practitioners who prescribe β-blockers
must be cognizant that as pregnancy progresses, the needs for drug may change.
Atenolol is a β-blocker also used in obstetrics. Polymorphisms in the eNOS gene are
associated with variations in the pharmacological response to atenolol. Patients with G498A
polymorphism in the eNOS gene have a better blood pressure response to atenolol. If
confirmed in larger studies, it is possible that the presence of eNOS polymorphisms could
help inform atenolol antihypertensive therapy [38].
Hydralazine is commonly used for acute treatment of severe hypertension [39]. Hydralazine
is metabolized by the enzyme NAT [40]. NAT has several polymorphisms that lead to
reduced enzymatic activity. This would potentially lead to higher concentrations of
hydralazine that might yield worsening side effects, such as hypotension. This has not been
studied in pregnancy to date. If a pregnant woman was known to have one of these SNPs, it
could lead to her not being administered hydralazine during a hypertensive emergency
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owing to the higher risk of hypotension and may lead to a different drug choice. This would
be one way that pharmacogenetics might play a role in individualized antihypertensive
therapy.
Antidepressant drugs
The mainstays of antidepressant therapy in pregnancy are SSRIs [41]. Several of the SSRI
drugs are metabolized by CYP2D6 [104]. In addition, several of them, such as fluoxetine,
also inhibit the enzyme. It is clear that even in women maintained on drug therapy,
depression symptoms typically worsen as pregnancy progresses [42]. Drug concentrations of
SSRIs also decrease in the third trimester. This is attributed to increased CYP2D6 activity
[43,44]. One study using paroxetine found that CYP2D6 genotype accounted for differences
in maternal plasma paroxetine concentrations during pregnancy [37]. In addition, as
pregnancy progressed, depressive symptoms in women who were EMs and UMs increased
significantly. The authors concluded that knowledge about a patient’s CYP2D6 genotype is
‘indispensable’ when prescribing paroxetine [37].
There are concerns regarding SSRI use and neonatal irritability symptoms and potential
small teratogenic risk increases [45]. It is possible that pharmacogenetic-informed
prescribing could help tailor the dose to help minimize potential adverse effects. More
research is needed on the pharmacogenetics of the adverse events associated with SSRI
therapy. There are now investigators advocating for the use of pharmacogenetic models to
inform therapeutic dosing decisions [46].
Preterm labor therapy
As the cause of the majority of neonatal morbidity and mortality, preterm labor is a major
focus of obstetric practice. The use of tocolytic medications to stop preterm labor is
commonplace but of varying success [47,48]. While many of the commonly used tocolytic
medications are substrates of polymorphic enzymes or target polymorphic receptors, there is
a paucity of data in this area. Whether the individual variation in success of tocolysis is due
to a less-than-concrete definition of preterm labor, differing pathophysiology of preterm
contractions or pharmacogenetic explanations, there remains work to be done in this area to
better individualize therapy.
Nifedipine is a calcium channel blocker used in obstetrics to stop contractions and delay
birth. It has been demonstrated that calcium channel blockers have a beneficial efficacy and
safety profile over other tocolytic classes of medication [49–51]. Nifedipine is metabolized
by the CYP3A family. Recent studies have demonstrated that polymorphisms in CYP3A5
and the use of CYP3A inhibitors can impact the concentration of nifedipine in maternal
blood [52,53]. While this is preliminary work, efforts have been underway to predict drug
concentrations in maternal blood based on CYP3A predicted activity [54]. As more data
emerge regarding the impact of genotype on drug concentration and the correlation with
pharmacodynamic changes of stopping contractions and preventing delivery, there may be
clinical applications of pharmacogenetics to this therapy. As this is a developing field,
however, more data are needed to populate and validate these models.
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The only FDA-approved drug for preterm labor is ritodrine. This β-adrenergic receptor (β2R)
agonist results in uterine smooth muscle relaxation. The side effects of ritodrine and other
β2R agonists such as terbutaline and hexoprenaline have lessened enthusiasm for these
therapies. The EMA went so far as to restrict the use of these medicines to a maximum of 48
h and only in women between 22 and 37 weeks of gestation [105]. In addition, the FDA
issued a black box warning against prolonged use of terbutaline for these reasons [106].
Even high drug concentrations of ritodrine have been noted not to inhibit labor [55]. Thus, it
may be at the β2R where differential response may be born. Some genotypes of the β2R have
been found to be protective against preterm delivery but the results did not show consistent
genotype associations [56,57]. One study demonstrated that Arg16 homozygosity of the β2R
improved the pregnancy outcome after hexoprenaline use [58]. We are unaware of any other
pharmacogenetic study of β2R agonists.
Prostaglandin inhibitors such as indomethacin have also been demonstrated to be effective
in treatment of preterm labor [50,51]. Indomethacin is metabolized by the polymorphic
CYP2C9 and CYP2C19 enzymes [59]. SNPs in these enzymes may affect the concentrations
of indomethacin and its effectiveness in preterm labor therapy, but we are unaware of any
studies in this area. As prostaglandin inhibitors also have fetal effects, they are typically
limited to use earlier in the preterm period [60]. Magnesium sulfate is another commonly
used tocolytic agent. We are also unaware of any pharmacogenetic studies on magnesium
sulfate as a tocolytic.
Antenatal corticosteroid administration is the most important therapy that can be given to a
woman in preterm labor [47]. Maternally administered to enhance the fetal lung maturation
in anticipation of preterm birth, antenatal corticosteroids reduce both neonatal mortality and
morbidity [61,62]. However, not all neonates receive the same benefit. Differences in
neonatal respiratory outcomes are seen in different ethnic groups, independent of gestational
age, weight and other sociodemographic factors [63–65]. In addition, respiratory distress
syndrome (RDS)-related mortality has a racial disparity that cannot be explained by
demographic factors [64]. Several studies are attempting to test for pharmacogenetic
explanations for this response variability. Betamethasone and dexamethasone are the
currently recommended options for antenatal corticosteroid therapy [47]. There are no
currently published studies to our knowledge that describe genetic influences on
corticosteroid drug concentrations in pregnancy. Much of the literature focuses on genotype
associations with outcomes. For instance glucocorticoids act at the glucocorticoid receptor
(GR). There are polymorphisms in the GR gene that can impact its response. Much of the
work in the GR and glucocorticoid pathway genes has come from asthma research [66,67].
While some SNPs create less functional GR activity, many polymorphisms in the pathway
genes lead to GR hypersensitivity [68]. Studies specifically of polymorphisms in GR have
shown certain haplotypes that may help determine clinical response [69], where one
specifically showed that a polymorphism in the GST-P1 gene may have an effect on RDS
[70]. In addition, a recent pharmacogenetic study looking at multiple CYP3A and other
betamethasone metabolic pathway SNPs and glucocorticoid pathway genes found that both
maternal and fetal genotypes were associated with RDS after betamethasone treatment when
controlling for gestational age and a host of other sociodemographic factors [71]. These
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findings included a fetal CYP3A7*1E genotype with an odds ratio of 23.68 (95% CI: 1.33–
420.6) for developing RDS. There were other SNPs significantly associated with long-term
respiratory morbidity such as bronchopulmonary dysplasia from the same cohort [72]. While
all of these studies are small and need to be confirmed in larger cohorts, there may be
potential for pharmacogenetic variation to help explain some of the outcome differences
from antenatal corticosteroids.
Nausea & vomiting of pregnancy
Nausea and vomiting of pregnancy (NVP) is a very common disorder, affecting up to 80%
of pregnant women [73]. Both mild and severe cases of NVP have a significant impact on
the quality of a woman’s life and can result in loss of time with family and time away from
work [74,75]. Many drugs are used to counteract NVP. These include vitamin B6,
doxylamine, promethazine, metoclopramide and ondansetron alone or in combination with
each other to name a few. Response to these drugs varies. Anesthesia literature has
documented that genotypes of drug-metabolizing enzymes and receptors may impact
therapeutic effectiveness of several of these drugs. A CYP2D6 substrate, ondansetron is a
drug whose failure has been linked to CYP2D6 EMs and UMs [76]. Many of the drugs
commonly given for NVP are substrates for polymorphic CYP450 enzymes. In addition,
many of the drugs act at the polymorphic serotonin receptor 5HT3. This receptor facilitates
the role of serotonin as a mediator of nausea and vomiting [77]. Variants in the 5HT3B
receptor are linked to increased nausea and vomiting due to increased response to serotonin
binding [78]. For women with NVP, one study demonstrated that SNPs in 5HT3B leading to
a high affinity receptor led to women needing more medication [79]. Other SNPs in the
5HT3A receptor were associated with more improvement in both NVP symptoms and
quality of life [79]. This study may be an initial foray into pharmacogenetics of NVP and
should be confirmed. However, it may lead to more individualized therapy for women with
NVP who have genotypes that might make a certain therapeutic drug option less effective.
Antiseizure drugs
Seizure disorders affect up to 2% of the population. Many women thus become pregnant
when taking drugs to prevent seizures. Many of these drugs are associated with teratogenic
effects. Drug concentrations are often monitored in pregnancy as concentrations change.
This often requires dose changes as the pregnancy progresses and in the postpartum period.
Some of this can be explained by the metabolism of some of the drugs. For instance,
phenytoin is metabolized by CYP2C9, a polymorphic enzyme that is induced in pregnancy
[80]. Some of the newer seizure drugs have favorable teratogenic and therapeutic profiles
[81]. One that is commonly used currently is lamotrigine. Lamotrigine clearance increases
several-fold in pregnancy [82–84]. This can lead to the need for higher doses during
pregnancy. Lamotrigine is metabolized through glucuronidation by enzymes that are both
polymorphic and often induced in pregnancy [85].
Obstetric anesthesia
In addition to utilizing antihypertensive medications and oral opioids listed above, there are
some potential areas where pharmacogenetics may influence obstetric anesthesia.
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Hypotension is a common side effect after spinal anesthesia. Response to stimulant therapy
for this is affected by the β2R genotype/haplotype [86]. In this study, less ephedrine was
needed to treat the hypotension in women carrying one or two alleles of the variant. Landau
points out that this may be one reason why numerous studies trying to prevent or treat
hypotension during spinal anesthesia for cesarean have failed to define a single ‘one size fits
all’ strategy [87]. Genetics may explain interindividual variation in this area. Additionally
SNPs in the μ-opioid receptor probably influence the pharmacodynamics of intrathecal
fentanyl [88]. These are just a few of the several areas where obstetric anesthesia is
embarking on pharmacogenetic research [87,89].
Pharmacogenetic horizon areas in obstetrics
There are a few other recent studies that highlight some areas where pharmacogenetics may
be utilized in obstetric therapeutics and management. The genetics of preeclampsia have
been analyzed multiple ways. The importance of both maternal and fetal genotype in this
disorder is apparent [90]. The endothelial isoform of nitric oxide synthase may be important
in the manifestations and the treatment of preeclampsia [38]. Smoking cessation is an
important goal of prenatal care. Recent findings that fetal GSTT1 deletion significantly
modifies the effect of smoking on birth weight may open windows into genotype and may
impact therapy for growth restriction [91]. The treatment of gestational diabetes has
undergone many changes in the last decade. The use of oral hypoglycemic agents has
diminished the use of insulin for patients. However, with the recent finding that typical
doses of glyburide for these women may lead to suboptimal drug concentrations [92],
pharmacogenetic impact studies on drug concentration variability are underway.
The patient’s perspective
The uptake of pharmacogenetics in clinical practice has been slow [12]. Much of this is due
to the paucity of data and pharmacogenetic-driven therapeutic trials. However, there is also a
lack of understanding on the part of clinicians. There is also a worry about how to best make
patients understand the science and nuance of pharmacogenetics in relation to their medical
therapy.
As researchers and practitioners postulate about future implementation, it is reassuring to
know that in general, most surveyed populations support collecting biological specimens for
research [93–95]. For pregnant women, the majority would give a specimen for DNA
analysis by either blood (needlestick) or saliva [96]. Making the transition from research to
clinical care, however, is less studied.
In an interesting follow-up study at Motherisk in Toronto, Madadi and colleagues asked
participants in a pharmacogenetic study about the communication of their information back
to them [97]. The diversity and complexity of questions that participants asked the
investigators underscore the need for supportive communication of results in the context of
personalized genetic information counseling. Some of the common suggestions by
participants related to having a short amount of time between the test and the results [97].
This is particularly relevant to pregnancy where decision for therapy cannot wait for several
years (the normal time cycle for research results). In addition, it was commonly brought up
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that genetic screening should be a routine part of prenatal screening or even to be carried out
before pregnancy. The clear message was that patients want to know if their genetic
information may impact their therapy or their babies. While this is only representative of a
small pregnant population, it is an area that will need further work.
Future perspective
Achieving individualized therapy in pregnancy (and in all of medicine) is a reachable goal.
Pharmacogenetics may be one tool to help achieve that goal. However, the current studies in
these areas are underpowered and observational. More data that combine genotypes,
pharmacokinetic information and pharmacodynamic outcomes are crucial to take steps
forward. In particular, the outcomes that need to garner focus for obstetric therapeutics are
the short- and long-term neonatal outcomes. These studies are expensive and difficult but
truly needed to understand if pharmacogenetic-driven therapy is truly a step forward.
Consideration of both maternal and fetal genotypes and building therapeutic models can
help supply clinicians with strategies for treatment. However, they will rely on robust data to
populate and validate the models. Only then will individualized pharmacotherapy in
pregnancy utilizing pharmacogenetics be realized.
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Executive summary
• ‘The right drug at the right dose at the right time for the right patient’ is the ideal
for individualized therapeutics.
• Most pregnant women take therapeutic drugs during their pregnancy.
• There is a paucity of pharmacokinetic and pharmacogenetic studies particularly
relating to pregnant women. This has delayed development in the field.
• Pharmacogenetic tests are used in other areas of medicine to help guide therapy.
These include tests for the drugs cetuximab, abacavir, carbamazepine and
imatinib. Other drugs with information supporting pharmacogenetic testing but
not yet commonly used are tamoxifen, venlafaxine, clopidogrel and warfarin.
• Breastfeeding women who have genotypes expressing CYP2D6 (extensive or
ultrarapid metabolizers) who also have a UGTB7*2 genotype may be at higher
risk for morphine toxicity in their infants. Thus a public health advisory warns
about this potential problem. SNPs in CYP2D6 can also play a role in maternal
pain control from other opioid drugs.
• Antihypertensive drugs such as β-blockers are metabolized through CYP2D6,
which may explain some of the variability in response. Other antihypertensive
drugs are also metabolized through polymorphic enzyme pathways.
• Some studies on SSRIs have found that polymorphisms in CYP450 enzymes
may play a role in their effectiveness. More studies are needed, particularly in
pregnancy relating to neonatal irritability syndrome.
• Preterm labor tocolytics are metabolized by polymorphic pathways or act at
polymorphic receptors. There are limited data regarding the impact of SNPs on
drug concentrations or effect.
• Some polymorphisms in glucocorticoid receptor pathways and CYP450s may be
associated with neonatal respiratory outcomes after antenatal corticosteroid
therapy.
• Drugs used for nausea and vomiting of pregnancy may demonstrate different
responses based on serotonin receptor SNPs.
• Patients have noted that they would like genetic information returned,
particularly if it would impact their future care or their baby’s health.
• There is a continuing imperative for more data combining pharmacokinetics,
pharmacodynamics and pharmacogenetics in order to build optimal therapeutic
models. The focus of these models needs to be on short- and long-term newborn
outcome optimization.
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Table 1
Drug-metabolizing enzymes and selected receptors with known polymorphisms affecting drug concentrations
and/or response and some commonly used drugs in pregnancy that are substrates of that enzyme.
Enzyme/receptor and specific SNP and functional significance Drugs metabolized
CYP2D6
*1/*1 with multiple copies = ultrarapid metabolizer
*4/*4, *4/*5, *5/*5 = poor metabolizer
*1/*1, *1/*2, *2/*2 = extensive metabolizer
Codeine, clonidine, fluoxetine, paroxetine, venlafaxine,
metoprolol, metoclopramide, ondansetron and
promethazine
CYP2C9
*1 = normal enzymatic activity
*3/*3 = decreased enzymatic activity (warfarin dose adjustment needed)
Fluoxetine, glyburide, ibuprofen and warfarin
CYP2C19
*1/*1 = normal enzymatic activity
*17/*17 = ultrarapid metabolizer
*2/*2, *3/*3, *2/*3 = poor metabolizer
Omeprazole and other proton pump inhibitors, phenytoin
and propranolol
CYP3A
CYP3A4*1B = decreased activity
CYP3A5*3 = decreased activity
CYP3A7 = some polymorphisms allow this fetal enzyme to persist into
adulthood
Chlorpheniramine, dexamethasone, indinavir and other
HIV antivirals, methadone, midazolam, nifedipine and
other calcium channel blockers, and propranolol
CYP2B6
*6 = decreased enzymatic activity
Bupropion and methadone
5HT3B receptor variant = high affinity receptor
5HT3A receptor variant = increased expression of subunit
Ondansetron and SSRI drugs
β2 adrenergic receptor
Arg16Gly = enhanced agonist-induced desensitization
Gln27Glu = resistance to desensitization
Ritodrine, terbutaline and hexoprenaline
Glucocorticoid receptor NR3C1
N363S = hypersensitivity
BclI = hypersensitivity
Betamethasone and dexamethasone
GST-P1 Ile105Val = reduced enzyme activity Betamethasone and dexamethasone
List not comprehensive.
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